---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-10-30T17:53:56.099967'
end_time: '2026-10-30T18:05:11.212589'
duration_seconds: 675.11
template_file: templates/disease_pathophysiology_research.md
template_sha: "f452f0a9c7e3536175154b9683c45663f686f283"
template_variables:
  disease_name: MASS Syndrome
  mondo_id: MONDO:0011431
  category: Mendelian
  causal_genes: FBN1
  omim_id: OMIM:604308
  synonyms: MASS phenotype
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
reference_validation:
  total_references: 17
  verified: 17
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  quotes_checked: 6
  quotes_valid: 4
  quotes_unsupported: 2
  unsupported_quote_references:
  - PMID:2739055
  - PMID:42274425
  relevance_assessed: 17
  on_topic: 16
  needs_review: true
  validator_version: 0.4.0
term_validation:
  total_terms: 47
  verified: 43
  not_found: 0
  obsolete: 2
  unverifiable: 2
  confabulation_rate: 0.0
  labels_checked: 16
  labels_matching: 2
  labels_mismatched: 9
  mislabelled_terms:
  - term_id: HP:0001065
    reported_labels:
    - Physical manifestation (skin)
    ontology_label: Striae distensae
  - term_id: HP:0002650
    reported_labels:
    - Clinical sign (skeletal)
    ontology_label: Scoliosis
  - term_id: HP:0001382
    reported_labels:
    - Clinical sign (skeletal)
    ontology_label: Joint hypermobility
  - term_id: HP:0001763
    reported_labels:
    - Physical manifestation
    ontology_label: Pes planus
  - term_id: HP:0000218
    reported_labels:
    - Physical manifestation
    ontology_label: High palate
  - term_id: HP:0000545
    reported_labels:
    - Clinical sign (ocular)
    ontology_label: Myopia
  - term_id: NCIT:C16818
    reported_labels:
    - transthoracic echocardiography
    - Imaging:* **transthoracic echocardiography
    ontology_label: Mammography
  - term_id: NCIT:C2667
    reported_labels:
    - Beta-Blocker
    ontology_label: Recombinant Fowlpox-TRICOM Vaccine
  - term_id: NCIT:C61876
    reported_labels:
    - Losartan
    ontology_label: Pancuronium
  labels_variant: 5
  obsolete_terms:
  - term_id: GO:0005578
    ontology_label: GO_0005578
    replaced_by: GO:0031012
  - term_id: GO:0062023
    ontology_label: obsolete collagen-containing extracellular matrix
    replaced_by: GO:0031012
  unresolvable_prefixes:
  - ORPHA
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: MASS_Syndrome-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: MASS_Syndrome-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** MASS Syndrome
- **MONDO ID:** MONDO:0011431 (if available)
- **Causal gene(s):** FBN1
- **OMIM:** OMIM:604308
- **Synonyms:** MASS phenotype
- **Category:** Mendelian

Many disease names are serial numbers ("... autosomal dominant 64", "... 26") that
do not say which gene the disease is about, and a similarly named disease with a
different gene is easy to research by mistake. Research the disease with the MONDO
ID and causal gene given above, and name its causal gene in your first paragraph.
If the name seems to point to a different gene or OMIM entry, follow the
identifiers above.

## Research Objectives

Please provide a comprehensive research report on **MASS Syndrome** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# MASS Syndrome (MASS Phenotype): Comprehensive Disease Characteristics Report

**Causal gene: FBN1 (fibrillin-1, HGNC:3603, 15q21.1).** MASS syndrome is a heritable connective-tissue disorder caused by heterozygous pathogenic variants in **FBN1**, the same gene responsible for Marfan syndrome. The acronym **MASS** denotes **M**itral valve prolapse, **A**ortic enlargement (borderline, non-progressive), and **S**kin and **S**keletal findings. It occupies a defined point on the phenotypic continuum of *type-1 fibrillinopathies*, distinguished from classic Marfan syndrome principally by the **absence of ectopia lentis** and the **absence of a progressive aortic root aneurysm**. Identifiers: **OMIM 604308**, **MONDO:0011431**.

> *Note on scope and evidence:* No patient-level dataset was provided; this report is synthesized from aggregated disease-level resources and primary literature (PubMed). Because MASS and Marfan syndrome are **allelic FBN1 disorders on one continuum**, much mechanistic, therapeutic, and model-organism evidence is derived from Marfan syndrome / FBN1 studies and is explicitly flagged as such. Evidence types are labeled: *human clinical*, *model organism*, *in vitro*, *computational/consensus*.

---

## 1. Disease Information

**Overview.** MASS phenotype was first delineated by **Glesby & Pyeritz (JAMA 1989, PMID 2739055)**, who observed that more than half of patients referred for a possible heritable connective-tissue disorder could not be classified in the existing nosology yet shared Marfan-like systemic features. They proposed the acronym MASS "to emphasize involvement of the mitral valve, aorta, skeleton, and skin," framing mitral valve prolapse (MVP) patients as "a continuum, from Marfan syndrome at one extreme to isolated mitral valve prolapse due to myxomatous proliferation of the valve leaflets" (*human clinical*, PMID 2739055). MASS is thus an **overlap connective-tissue disorder**: patients have mild aortic root dilatation and MVP with systemic (skin/skeletal) findings, but do **not** meet full criteria for Marfan syndrome and lack lens dislocation.

**Key identifiers.**
- **OMIM:** 604308 (MASS SYNDROME; MASS PHENOTYPE)
- **MONDO:** MONDO:0011431
- **Orphanet:** MASS falls within the Marfan/type-1-fibrillinopathy spectrum (ORPHA:284963 "Marfanoid–overlap" spectrum; no unique high-level ORPHA code is universally applied — *data incompletely standardized*)
- **ICD-10:** Q87.4 relates to Marfan syndrome; MASS has no distinct ICD-10 code and is usually coded under connective-tissue/MVP categories (I34.1 mitral valve prolapse; Q87.4) — *not uniquely coded*
- **ICD-11:** LD28.0 (Marfan syndrome) / connective-tissue categories — *not uniquely coded*
- **MeSH:** No dedicated MeSH term; indexed under "Marfan Syndrome" / "Mitral Valve Prolapse" / "Connective Tissue Diseases"
- **Gene:** FBN1 — HGNC:3603, NCBI Gene 2200, Ensembl ENSG00000166147, UniProt P35555; gene-level OMIM *134797*

**Synonyms / alternative names.** MASS phenotype; MASS spectrum; mitral valve–aorta–skeleton–skin syndrome. (Historically grouped with "marfanoid" and "overlap heritable connective-tissue disorder.")

**Information source.** Disease-level / aggregated resources and primary literature (not EHR-derived).

**Ontology:** MONDO:0011431; disease class — Mendelian connective-tissue disorder.

---

## 2. Etiology

**Primary cause — genetic.** MASS is a **monogenic, autosomal-dominant** disorder caused by heterozygous pathogenic variants in **FBN1**. There is no infectious or primary environmental cause. FBN1 "encodes fibrillin-1, a large glycoprotein which is a major component of microfibrils that are widely distributed in structural elements of elastic and non-elastic tissues" (*human clinical/review*, PMID 26875674). The same review groups MASS among the "type-1 fibrillinopathies," which "include Marfan syndrome (MFS), MASS syndrome … [and] Familial ectopia lentis."

**Genetic risk factors.**
- *Causal variants:* heterozygous FBN1 variants (see §4). The pathogenic FBN1 allele is both necessary and, with age-dependent penetrance, sufficient.
- *Modifier genes / genetic background:* variable expressivity within and between families implies modifier effects; specific robust MASS modifier loci are **not established** (*data not available*). Candidate modifiers in the broader fibrillinopathy literature include genes of the TGF-β axis.
- *Family history* is the dominant risk factor (50% transmission risk from an affected parent).

**Environmental risk factors.** None cause MASS. However, **hemodynamic/mechanical stress** (hypertension, isometric/heavy resistance exercise, pregnancy) is an aggravating factor for the aortic and valvular components across the FBN1 spectrum; pregnancy increases cardiovascular risk and aortic events in FBN1 disorders (*human clinical*, PMID 42880760; PMID 20351702). Age and (for aortic outcomes) male sex modulate cardiovascular expression.

**Protective factors.** No genetic protective alleles are defined for MASS. Pharmacologic "protection" against aortic growth (beta-blockers, ARBs) and lifestyle modification (avoidance of competitive/isometric sport, blood-pressure control) reduce cardiovascular risk (*human clinical*, PMID 30261963).

**Gene–environment interactions.** The FBN1 lesion sets a structurally weakened, TGF-β–dysregulated extracellular matrix; superimposed mechanical wall stress then drives the cardiovascular phenotype. This gene × hemodynamic-load interaction underlies the rationale for mechanical-stress-reducing therapy (*model organism / human clinical*, PMID 17892982; PMID 41195532).

---

## 3. Phenotypes

MASS is defined by a **tetrad** of organ systems with **variable expressivity** and generally **mild-to-moderate** severity. By definition the aortic component is borderline and the lens is normal. Onset is typically **childhood to young adulthood**; most features are slowly **progressive or stable** rather than episodic.

| Phenotype | Type | HPO term | Onset / course | Frequency (qualitative) |
|---|---|---|---|---|
| Mitral valve prolapse (± mitral regurgitation) | Clinical sign (cardiac) | HP:0001634 / HP:0001653 | Childhood–adult; may progress | Core/common |
| Borderline aortic root dilatation (Z-score <2, non-progressive) | Clinical sign (cardiac) | HP:0002616 (aortic root aneurysm, mild) | Young adult; **non-progressive by definition** | Core/common |
| Striae atrophicae (skin striae) | Physical manifestation (skin) | HP:0001065 | Adolescence+ | Common |
| Skin hyperextensibility / thin skin | Physical manifestation (skin) | HP:0007429 / HP:0000974 | Childhood | Variable |
| Tall/long limbs, dolichostenomelia | Physical manifestation (skeletal) | HP:0001519 / HP:0001166 (arachnodactyly) | Childhood | Variable |
| Pectus excavatum / carinatum | Physical manifestation (skeletal) | HP:0000767 / HP:0000768 | Childhood–adolescence | Common |
| Scoliosis | Clinical sign (skeletal) | HP:0002650 | Childhood–adolescence | Variable |
| Joint hypermobility | Clinical sign (skeletal) | HP:0001382 | Congenital/childhood | Common |
| Pes planus (flat feet) | Physical manifestation | HP:0001763 | Childhood | Common |
| High-arched palate | Physical manifestation | HP:0000218 | Congenital | Variable |
| Myopia (mild, **no ectopia lentis**) | Clinical sign (ocular) | HP:0000545 | Childhood | Variable |

**Explicitly ABSENT / excluded (key discriminators):** ectopia lentis (HP:0001083) and progressive aortic aneurysm/dissection — their presence reclassifies the patient toward Marfan syndrome (*human clinical*, PMID 20591885; PMID 2739055).

**Severity / progression.** Generally mild and non-life-threatening; skeletal and skin features are static or slowly progressive. MVP can progress to significant mitral regurgitation in a minority. Because "the clinical phenotype … constitutes a continuum" (PMID 2739055), individual severity varies widely.

**Quality-of-life impact.** Usually modest: musculoskeletal pain, fatigue, joint instability, and body-image concerns from skeletal/skin features; palpitations/arrhythmia and exertional limitation when MVP/regurgitation is significant. No MASS-specific EQ-5D/SF-36 datasets exist (*data not available*); QoL inference is drawn from the broader MVP/connective-tissue literature.

---

## 4. Genetic / Molecular Information

**Causal gene.** **FBN1** — fibrillin-1; HGNC:3603; NCBI Gene 2200; Ensembl ENSG00000166147; UniProt **P35555**; cytogenetic locus **15q21.1**; gene OMIM 134797; 65–66 coding exons (PMID 26875674).

**Pathogenic variants.**
- *Gene(s) affected:* FBN1 (single gene).
- *Variant classification (ACMG/AMP):* pathogenic / likely pathogenic FBN1 variants; a large fraction of rare FBN1 missense changes remain VUS, complicating MASS (a mild-phenotype) diagnosis. Interpretation uses ClinVar/ClinGen and the FBN1-specific literature.
- *Variant type/class:* predominantly **missense**, classically **cysteine substitutions within calcium-binding EGF-like (cbEGF) domains** that disrupt disulfide bonding and calcium binding (the same class modeled by the mouse *Fbn1^C1039G* allele; §15). Also nonsense, frameshift, splice-site, and in-frame deletions. Sibling cases with isolated skeletal Marfan features and no cardiac/ocular findings carried the recurrent missense **R2726W (p.Arg2726Trp)**, illustrating how particular FBN1 alleles produce mild/partial phenotypes (*human clinical*, PMID 26875674).
- *Allele frequency:* pathogenic FBN1 variants are individually **ultra-rare** in gnomAD (most absent or singletons); FBN1 is constrained against loss-of-function.
- *Somatic vs germline:* **germline** (constitutional); de novo variants occur (as in Marfan, ~25% de novo).
- *Functional consequence:* two principal mechanisms — (i) **dominant-negative** (mutant fibrillin-1 monomers poison microfibril assembly), typical of cbEGF cysteine missense; and (ii) **haploinsufficiency** (premature-termination/null alleles reducing fibrillin-1 quantity). Both converge on impaired microfibril function and dysregulated TGF-β sequestration (*human clinical/review*, PMID 26919284).

**Genotype–phenotype note.** No FBN1 variant is pathognomonic for MASS specifically; MASS reflects the *milder end* of FBN1 expression, and the same variant can produce Marfan syndrome, MASS, or isolated features in different individuals/families (variable expressivity; PMID 2739055, PMID 26875674).

**Modifier genes.** Not firmly established for MASS (*data not available*); modifiers of the TGF-β axis are hypothesized.

**Epigenetic information.** No MASS-specific DNA-methylation/histone signature is established (*data not available*). (Epitranscriptomic A-to-I RNA editing dysregulation has been reported in Marfan aortic smooth muscle, PMID 42794678 — *disease-spectrum, not MASS-specific*.)

**Chromosomal abnormalities.** None characteristic; MASS is a single-nucleotide/small-indel disorder, not a copy-number/aneuploidy syndrome. Large FBN1 deletions are rare.

**Ontology:** gene FBN1 (HGNC:3603); GO:0005201 extracellular matrix structural constituent; GO:0005520 insulin-like growth factor binding (fibrillin domains); CHEBI:29108 calcium(2+) (cbEGF calcium binding).

---

## 5. Environmental Information

- **Environmental factors (toxins/radiation/occupational):** none cause MASS (*not applicable* as etiology). Mechanical wall stress and hypertension aggravate the cardiovascular component.
- **Lifestyle factors:** strenuous isometric/competitive exercise and poorly controlled blood pressure increase aortic/valvular risk; smoking and stimulants are discouraged. Pregnancy is a high-load state warranting cardiovascular surveillance (*human clinical*, PMID 42880760).
- **Infectious agents:** none (*not applicable*). Standard endocarditis-prophylaxis considerations may apply to significant mitral valve disease per general cardiology guidelines.

---

## 6. Mechanism / Pathophysiology

### Ordered causal chain (initiating lesion → clinical manifestation)

1. A heterozygous **FBN1 variant** (most often a cbEGF-domain cysteine missense; alternatively a null allele) **results in** structurally abnormal or quantitatively reduced **fibrillin-1 monomers**.
2. Abnormal/insufficient fibrillin-1 **leads to** defective **microfibril assembly and reduced extracellular-matrix integrity** in elastic and non-elastic connective tissue (dominant-negative *or* haploinsufficient mechanism) (*review*, PMID 26875674).
3. Defective microfibrils **result in loss of normal sequestration of latent TGF-β** in the matrix, which **leads to** increased bioavailability and **enhanced TGF-β / Smad2/3 signaling** (*inferred from spectrum data and mouse models*; PMID 26919284).
4. The chain then **branches**:
   - **4a (Cardiac–valve branch):** enhanced TGF-β signaling + weak valvular matrix **leads to** **myxomatous degeneration of the mitral valve** → mitral valve prolapse ± regurgitation. "Enhanced TGF-β signaling caused by mutations in Fibrillin-1 (FBN1) … leads to myxomatous degeneration of the mitral valve" (*model organism*, PMID 42274425).
   - **4b (Cardiac–aortic branch):** weakened aortic medial elastic lamellae + altered smooth-muscle mechanosignaling **result in** **mild aortic root dilatation**; in MASS this branch is **attenuated/non-progressive** (Z-score <2), whereas in Marfan it progresses to aneurysm/dissection (*human clinical*, PMID 20591885; mechanosignaling e.g. FGF12, PMID 41540272 — *disease-spectrum*).
   - **4c (Skin branch):** reduced dermal elastic-fiber integrity **leads to** **striae atrophicae / skin laxity**.
   - **4d (Skeletal branch):** altered TGF-β/BMP signaling in perichondrium/periosteum **leads to** **bone overgrowth, pectus deformity, scoliosis, joint laxity** (*inferred from Marfan skeletal biology*).
5. Collectively these tissue-level changes **produce** the clinical MASS tetrad; the *absence* of lens zonule disruption (normal ciliary-zonule fibrillin function in these individuals) **explains the lack of ectopia lentis** that separates MASS from Marfan.

### Supporting detail
- **Molecular pathways:** TGF-β receptor signaling (GO:0007179) via Smad2/3; secondary non-canonical ERK/MAPK and AngII–AT1R mechanotransduction (rationale for ARBs; PMID 41195532). Reactome: "Molecules associated with elastic fibres," "Signaling by TGF-beta."
- **Cellular processes:** extracellular-matrix disassembly/remodeling, fibrosis, inflammation (macrophage infiltration in degenerating valves; PMID 42274425), altered vascular smooth-muscle-cell phenotype.
- **Protein dysfunction:** fibrillin-1 misassembly / reduced incorporation into microfibrils; dominant-negative poisoning of multimers; loss-of-function haploinsufficiency.
- **Tissue-damage mechanisms:** elastic-fiber fragmentation and medial changes; myxomatous valvular proteoglycan accumulation.
- **Immune involvement:** low-grade, secondary (macrophage infiltration in valve degeneration; *model organism*, PMID 42274425); not autoimmune.
- **Metabolic/biochemical:** no primary enzyme defect; a structural/signaling ECM disorder. (Metabolic modifiers of aortic disease, e.g., LDHA/lactate, reported in Marfan mice — PMID 42364561, *disease-spectrum*.)

**Upstream vs downstream:** FBN1 variant (upstream) → microfibril/TGF-β dysregulation (intermediate) → organ phenotypes (downstream).
**Cell types (CL):** CL:0000359 vascular associated smooth muscle cell; CL:0002548 fibroblast of cardiac tissue / valve interstitial cell; CL:0000057 fibroblast (dermal); CL:0000136? (not used) — chondrocyte/osteoblast lineages (skeletal).
**GO biological processes:** GO:0048251 elastic fiber assembly; GO:0030199 collagen fibril organization; GO:0007179 TGF-β receptor signaling pathway; GO:0030198 extracellular matrix organization.
**Subcellular (GO cellular component):** GO:0005578 proteinaceous extracellular matrix; GO:0062023 collagen-containing extracellular matrix; GO:0001527 microfibril.

---

## 7. Anatomical Structures Affected

**Organ level (primary):**
- **Mitral valve** (UBERON:0002135) — myxomatous degeneration, prolapse.
- **Aorta / aortic root (sinuses of Valsalva)** (UBERON:0000947; UBERON:0004178 root) — mild, non-progressive dilatation.
- **Skin** (UBERON:0002097) — striae, laxity.
- **Skeleton / axial & appendicular bones, thoracic cage, vertebral column** (UBERON:0004288 skeleton; UBERON:0003129 skull; UBERON:0001130 vertebral column) — overgrowth, pectus, scoliosis.
- **Joints** (UBERON:0000982) — hypermobility.

**Body systems:** cardiovascular (primary), integumentary, musculoskeletal; ocular (mild myopia only).

**Secondary/complication organs:** left atrium/ventricle (volume overload from mitral regurgitation); feet (pes planus).

**Tissue/cell level:** **connective tissue** (elastic and collagenous ECM) is the unifying target. Cells: vascular smooth muscle cells (CL:0000359), valve interstitial cells/fibroblasts, dermal fibroblasts (CL:0000057), chondrocytes/osteoblasts (skeletal).

**Subcellular:** extracellular **microfibril** (GO:0001527) and elastic fiber; secretory pathway of fibrillin-1.

**Localization / lateralization:** systemic and **bilateral/symmetric**; cardiac lesions are central (mitral valve, aortic root).

---

## 8. Temporal Development

- **Onset:** congenital genotype; clinical features typically emerge in **childhood to young adulthood**; insidious, chronic onset.
- **Progression:** generally **stable to slowly progressive**. The defining aortic component is **non-progressive** (Z<2). MVP may progress to significant mitral regurgitation in a subset; scoliosis/pectus can progress during pubertal growth.
- **Disease course / duration:** **chronic, lifelong.**
- **Patterns / remission:** no spontaneous remission; features are managed, not cured.
- **Critical periods / vulnerability windows:** pubertal growth spurt (skeletal progression); **pregnancy** (cardiovascular load; PMID 42880760); importantly, **childhood evaluations may be inconclusive** — the revised Ghent nosology cautions that mild/young presentations require **serial re-evaluation** because aortic or ocular features may declare later and reclassify MASS as Marfan syndrome (*human clinical*, PMID 20591885).

---

## 9. Inheritance and Population

- **Inheritance:** **autosomal dominant** (HP:0000006). ~50% transmission risk; de novo variants occur.
- **Penetrance:** high but **age-dependent and feature-dependent**; **expressivity is highly variable** even within a family (PMID 2739055).
- **Epidemiology:** no MASS-specific prevalence figure is established. As a mild FBN1 fibrillinopathy it sits within the broader spectrum; **Marfan syndrome prevalence is ~2–3 per 10,000 births** (~20–30 per 100,000) (*human clinical*, PMID 21904900), and MASS/overlap phenotypes are plausibly at least as common but under-ascertained (*data not fully available*).
- **Anticipation:** none (not a repeat-expansion disorder).
- **Germline mosaicism:** reported for FBN1 generally; relevant to recurrence counseling (*spectrum data*).
- **Founder effects / consanguinity:** not characteristic (dominant, pan-ethnic); consanguinity not relevant.
- **Carrier frequency:** not applicable (dominant; "carriers" are affected).
- **Population demographics:** pan-ethnic, worldwide; no strong ethnic predilection. **Sex:** both sexes affected; aortic complications across the FBN1 spectrum trend more severe in males, while MVP/mitral regurgitation is somewhat more frequent in females (*human clinical*, PMID 23622922).

---

## 10. Diagnostics

**Diagnostic framework — revised Ghent nosology (2010).** MASS is diagnosed when there is MVP, borderline aortic involvement (**aortic root Z-score <2**), systemic connective-tissue features (systemic score typically ≥5), and **no ectopia lentis**, in a patient not meeting Marfan criteria (*human clinical*, PMID 20591885). "Diagnosis should be established using the revised Ghent nosology in combination with genotypic analysis in specialized Marfan centres" (PMID 21904900).

**Clinical tests.**
- *Imaging:* **transthoracic echocardiography** (NCIT:C16818) — aortic root Z-score, MVP, mitral regurgitation; serial surveillance. CT/MRI angiography for complete aortic assessment when indicated.
- *Ophthalmology:* **slit-lamp examination with dilated pupils** to exclude ectopia lentis (key discriminator).
- *Skeletal assessment:* systemic-score maneuvers (wrist/thumb sign, arm-span/height, pectus, scoliosis, pes planus, facial features), spine radiographs as needed.
- *Laboratory:* **no diagnostic blood/urine biomarker** exists; homocysteine/urine amino acids to exclude homocystinoria in differential.
- *Pathology (if valve resected):* myxomatous proteoglycan-rich degeneration.

**Genetic testing.** **FBN1 molecular analysis** is central: single-gene sequencing + deletion/duplication analysis, or (preferred) a **multigene aortopathy/connective-tissue NGS panel** covering FBN1, TGFBR1, TGFBR2, SMAD3, TGFB2, TGFB3, ACTA2, MYH11, COL3A1, etc., to resolve the differential. WES/WGS are useful when panels are negative. Chromosomal microarray/karyotype/FISH/mtDNA/repeat testing are **not indicated** (not a CNV/mitochondrial/repeat disorder). NCIT:C16858 Genetic Testing.

**Omics-based diagnostics:** not used clinically for MASS (*not applicable*).

**Clinical criteria:** revised Ghent nosology (2010) is the standard (PMID 20591885).

**Differential diagnosis:**
- **Marfan syndrome** — ectopia lentis and/or progressive aortic root aneurysm (Z≥2) present.
- **Loeys–Dietz syndrome** — arterial tortuosity, hypertelorism, bifid uvula; TGFBR1/2, SMAD3, TGFB2/3.
- **Ehlers–Danlos syndromes** — skin/joint predominance; vascular EDS (COL3A1).
- **Isolated/familial MVP** and **familial ectopia lentis** (allelic FBN1).
- **Homocystinuria** — lens dislocation + thrombosis + biochemical markers.

**Screening:** no newborn/population screening. **Cascade clinical + genetic screening of first-degree relatives** is recommended once a familial FBN1 variant is identified.

---

## 11. Outcome / Prognosis

- **Survival / life expectancy:** generally **favorable and near-normal**, because MASS **lacks the progressive aortic aneurysm** that drives mortality in Marfan syndrome — where "aortic disease is the main cause of death" and, before surgery, "most patients died in the fourth decade of life" (*human clinical*, PMID 20351702). MASS mortality is not elevated by the defining phenotype.
- **Disease-specific mortality:** low; no MASS-specific mortality registry (*data not available*). Risk would rise only if a patient is actually on the Marfan end of the spectrum (hence surveillance).
- **Morbidity / function:** mainly musculoskeletal (pain, scoliosis, pectus, joint instability), significant mitral regurgitation in a minority (→ arrhythmia, heart failure, rarely need for valve repair/replacement), and skin changes. Disability is usually mild.
- **Complications:** progressive mitral regurgitation; development/declaration of aortic dilatation over time (reclassification); pregnancy-related cardiovascular risk.
- **Prognostic factors:** degree and progression of aortic root dimension and mitral regurgitation; genotype (null vs dominant-negative) and family history of dissection; age and sex.
- **Prognostic biomarkers:** none validated specifically for MASS; serial aortic Z-score and echo are the practical predictors (*human clinical*).
- **QoL measures:** no MASS-specific EQ-5D/SF-36/PROMIS data (*data not available*).

---

## 12. Treatment

There is **no cure and no disease-specific drug**; management targets the cardiovascular component and symptomatic skeletal issues, mirroring fibrillinopathy care.

**Pharmacotherapy (cardiovascular, when aortic dilatation/MVP warrants):**
- **Beta-blockers** (e.g., atenolol) — reduce hemodynamic wall stress/aortic growth. NCIT:C2667 (Beta-Blocker); atenolol NCIT:C236.
- **Angiotensin II receptor blockers** (losartan) — attenuate TGF-β/AT1R-driven aortic pathology; NCIT:C61876 (Losartan). In Marfan RCTs, "Aortic root diameter increased with no differences between groups: 0.4 mm/year" for losartan vs atenolol — i.e., **comparable aortic protection** (*human clinical RCT*, PMID 30261963; PMID 23622922). Inverse-agonist ARB activity is mechanistically important (*model organism*, PMID 41195532).
- *Pharmacogenomics:* no FBN1-specific PGx guidance (*not applicable*).

**Advanced therapeutics:** **gene therapy, cell therapy, RNA-based therapy, immunotherapy — none approved or standard; not applicable** to MASS currently (*data not available*). Allele-specific/ASO approaches are conceptual for dominant-negative FBN1.

**Surgical/interventional:** rarely needed for MASS; **mitral valve repair/replacement** for severe mitral regurgitation; prophylactic aortic root surgery is generally **not required** in true MASS (reserved for Marfan-range aortic dilatation; valve-sparing root replacement/David procedure or Bentall when applicable — PMID 21904900).

**Supportive/rehabilitative:** physical therapy for scoliosis/joint instability; orthotics for pes planus; orthopedic management of pectus/scoliosis; pain management; activity counseling (avoid isometric/competitive sports with significant cardiac involvement).

**Experimental:** FBN1-spectrum trials (e.g., ARB/beta-blocker comparisons; emerging TGF-β and metabolic targets) are Marfan-focused (*disease-spectrum*, PMIDs 30261963, 42364561). No MASS-specific NCT trials identified (*data not available*).

**Treatment strategy:** individualized, severity-based; combination beta-blocker + ARB is used in some aortic cases; genotype-guided risk stratification and multidisciplinary (cardiology, genetics, orthopedics, ophthalmology) care.

---

## 13. Prevention

- **Primary prevention:** not possible (germline genetic cause). **Preimplantation genetic testing (PGT-M)** and **prenatal diagnosis** can prevent transmission when a familial FBN1 variant is known.
- **Secondary prevention:** **serial echocardiographic surveillance** of the aortic root and mitral valve for early detection of progression/reclassification; ophthalmologic monitoring.
- **Tertiary prevention:** beta-blocker/ARB therapy, blood-pressure control, activity modification, endocarditis-risk awareness, and pregnancy planning to prevent complications (*human clinical*, PMID 42880760).
- **Immunization / public-health / environmental / infectious interventions:** not applicable.
- **Genetic counseling:** essential — autosomal-dominant 50% recurrence risk, variable expressivity, importance of cascade testing and longitudinal re-evaluation; per ACMG/NSGC/GeneReviews frameworks.
- **Risk stratification:** identify relatives carrying the familial variant for targeted surveillance.

---

## 14. Other Species / Natural Disease

- **Taxonomy / orthologs:** human FBN1 (Gene 2200); mouse **Fbn1** (NCBI Gene 14118; NCBI Taxon **10090**, *Mus musculus*); rat Fbn1 (Taxon 10116); zebrafish *fbn1* (Taxon 7955). Fibrillin-1 and microfibril biology are **evolutionarily conserved** across vertebrates.
- **Natural disease in other species:** fibrillinopathies/elastic-fiber disorders occur in animals; a **bovine FBN1-associated connective-tissue/"Marfan-like" syndrome** is catalogued in OMIA (fibrillin-1 cattle). MASS as a named entity is human-specific; comparable overlap phenotypes are not formally defined in veterinary medicine (*data limited*).
- **Comparative pathology:** animal FBN1 disruption reproduces aortic/valvular and elastic-fiber pathology, supporting conserved mechanism.
- **Transmission / zoonosis:** not applicable (genetic disorder).

---

## 15. Model Organisms

- **Principal model — mouse.** The heterozygous knock-in **Fbn1^C1039G/+** (cysteine substitution in a cbEGF domain — the same variant *class* seen in patients) is the standard FBN1-fibrillinopathy model. It recapitulates **myxomatous mitral valve degeneration/prolapse**, **progressive thoracic aortic aneurysm**, and **elastic-fiber fragmentation**, driven by **enhanced TGF-β signaling** (*model organism*, PMID 42274425; PMID 42222959). Secondary elastic-tissue phenotypes (e.g., lacrimal-gland dysfunction) also appear (PMID 41533936).
- **Other genetic models:** hypomorphic/null Fbn1 alleles (e.g., mgR, mgΔ) model haploinsufficiency/severe disease; conditional and transgenic lines exist.
- **Model types:** mammalian in vivo (mouse, rat); zebrafish *fbn1*; patient-derived fibroblasts/iPSC-derived smooth-muscle and valve cells (in vitro).
- **Translational use / applications:** these models established the **TGF-β–antagonism rationale**: "treatment with losartan normalized aortic root growth and aortic wall architecture" in an FBN1-targeted mouse (*model organism*, PMID 17892982), directly motivating human ARB trials. They are used to dissect mechanosignaling (FGF12; PMID 41540272), immune/lymphatic contributions to valve degeneration (PMID 42274425), and metabolic modifiers (PMID 42364561).
- **Model limitations (for MASS specifically):** existing mice model the **Marfan (progressive-aortic) end** of the spectrum; they do **not** cleanly reproduce the *mild, non-progressive aortic* MASS phenotype, so MASS-specific genotype–phenotype questions (why some FBN1 alleles yield only MASS) remain **under-modeled**.
- **Resources:** MGI (Fbn1), IMPC/IMSR, Alliance of Genome Resources, ZFIN.

---

## Evidence Summary (key PMIDs)

| PMID | Type | Contribution |
|---|---|---|
| 2739055 | Human clinical | Original MASS definition; phenotypic continuum |
| 20591885 | Human clinical (criteria) | Revised Ghent nosology; MASS vs Marfan discriminators |
| 26875674 | Human clinical/review | FBN1/fibrillin-1 biology; type-1 fibrillinopathy spectrum; R2726W mild allele |
| 26919284 | Review | FBN1→TGF-β pathway; therapeutic shift to TGF-β antagonism |
| 42274425 | Model organism | FBN1→TGF-β→myxomatous mitral valve degeneration |
| 42222959 | Model organism | Standard Marfan mouse aortic model |
| 17892982 | Model organism/clinical rationale | Losartan normalizes aortic growth in FBN1 mouse |
| 30261963 / 23622922 | Human clinical RCT | Losartan vs atenolol aortic outcomes |
| 21904900 | Human clinical | Prevalence 2–3/10,000; combined Ghent+genotype diagnosis; aortic surgery |
| 20351702 | Human clinical | Marfan mortality driven by aortic disease |
| 42880760 | Human clinical | Pregnancy cardiovascular risk in FBN1 disorders |
| 41195532 / 41540272 / 42364561 | Model organism | ARB mechanism; mechanosignaling; metabolic modifiers (spectrum) |

## Limitations and Future Directions
1. **MASS-specific data are sparse;** much evidence is extrapolated from Marfan/FBN1-spectrum studies (explicitly flagged). Dedicated MASS natural-history cohorts, prevalence, QoL, and mortality data are needed.
2. **Genotype–phenotype determinants** of why specific FBN1 alleles yield only the mild MASS phenotype are unresolved; modifier genes are uncharacterized.
3. **No MASS-specific model** reproduces the non-progressive aortic phenotype.
4. **Diagnostic caution:** MASS in children/young adults may evolve toward Marfan; longitudinal re-evaluation is essential.


## Artifacts

- [OpenScientist final report](MASS_Syndrome-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](MASS_Syndrome-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.4.0.

| Outcome | Count |
| --- | --- |
| References checked | 17 |
| Resolved | 17 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| Quoted claims checked | 6 |
| Quoted claims found in source | 4 |
| Quoted claims **not** found in source | 2 |
| References weighed for topical relevance | 17 |
| On topic | 16 |
| Off topic | 0 |

### Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked *abstract only* below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

- `PMID:2739055` *(abstract only)*: "the clinical phenotype … constitutes a continuum"
  - closest text in source: "The clinical phenotype of patients with mitral valve prolapse constitutes a continuum, from Marfan syndrome at one extreme to isolated mitral valve prolapse due to myxomatous proliferation of the valve leaflets"
- `PMID:42274425` *(abstract only)*: "Enhanced TGF-β signaling caused by mutations in Fibrillin-1 (FBN1) … leads to myxomatous degeneration of the mitral valve"
  - closest text in source: "Enhanced TGF-β signaling caused by mutations in Fibrillin-1 (FBN1) in patients with Marfan syndrome (MFS) leads to myxomatous degeneration of the mitral valve (MDMV)"

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 47 |
| Resolved | 43 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 2 |
| Unverifiable | 2 |
| Terms whose name was checked | 16 |
| Terms named correctly | 2 |
| Terms named as a **different** term | 9 |
| Terms whose name is worth a second look | 5 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `HP:0001065` (1 mention) - the report calls it "Physical manifestation (skin)"; HP calls it **Striae distensae**
- `HP:0002650` (1 mention) - the report calls it "Clinical sign (skeletal)"; HP calls it **Scoliosis**
- `HP:0001382` (1 mention) - the report calls it "Clinical sign (skeletal)"; HP calls it **Joint hypermobility**
- `HP:0001763` (1 mention) - the report calls it "Physical manifestation"; HP calls it **Pes planus**
- `HP:0000218` (1 mention) - the report calls it "Physical manifestation"; HP calls it **High palate**
- `HP:0000545` (1 mention) - the report calls it "Clinical sign (ocular)"; HP calls it **Myopia**
- `NCIT:C16818` (1 mention) - the report calls it "transthoracic echocardiography", "Imaging:* **transthoracic echocardiography"; NCIT calls it **Mammography**
- `NCIT:C2667` (1 mention) - the report calls it "Beta-Blocker"; NCIT calls it **Recombinant Fowlpox-TRICOM Vaccine**
- `NCIT:C61876` (1 mention) - the report calls it "Losartan"; NCIT calls it **Pancuronium**

### Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

- `GO:0005578` (GO_0005578) (1 mention) - replaced by `GO:0031012`
- `GO:0062023` (obsolete collagen-containing extracellular matrix) (1 mention) - replaced by `GO:0031012`

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `HP:0002616` (1 mention) - the report calls it "aortic root aneurysm, mild"; HP calls it **Aortic root aneurysm**
- `GO:0007179` (2 mentions) - the report calls it "Molecular pathways:** TGF-β receptor signaling"; GO calls it **transforming growth factor beta receptor signaling pathway**, and lists "TGF-beta receptor signaling pathway" among its other names
- `UBERON:0002097` (1 mention) - the report calls it "Skin"; UBERON calls it **skin of body**, and lists "skin" among its other names
- `UBERON:0000982` (1 mention) - the report calls it "Joints"; UBERON calls it **skeletal joint**, and lists "joints" among its other names
- `HP:0000006` (1 mention) - the report calls it "autosomal dominant", "Inheritance:** **autosomal dominant"; HP calls it **Autosomal dominant inheritance**, and lists "Autosomal dominant" among its other names

### Terms named inconsistently

The report gives these identifiers more than one name of its own:

- `HP:0000006` - called "autosomal dominant", "Inheritance:** **autosomal dominant"
- `NCIT:C16818` - called "transthoracic echocardiography", "Imaging:* **transthoracic echocardiography"

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `ORPHA`.